Breast Cancer Index

At the 2023 JADPRO Live, Mayra Lima, APRN, MSN reviews a Breast Cancer Index patient case study and how the BCI results positively impacted her patient’s quality of life. Watch here: https://bit.ly/4b8teVH For intended use and limitations, visit breastcancerindex.com. Speakers listed are consultants for Biotheranostics, Inc. Statements reflect the speakers’ own personal views and interpretations.

Understand how the Breast Cancer Index® test identifies patients with a low risk of late distant recurrence, helping to personalize extended endocrine therapy treatment decisions. Learn from our recent webinar to help avoid over- and under-treatment. Watch here: https://bit.ly/3zv9aPx

At the 2023 JADPRO Live, Linda Moors, PA-C, Marla Sustin, NP, and Mayra Lima, APRN, MSN highlight the important role that advanced practitioners play when it comes to making decisions about extended endocrine therapy. Watch here: https://bit.ly/3Wxofti For intended use and limitations, visit breastcancerindex.com. Speakers listed are consultants for Biotheranostics, Inc. Statements reflect the speakers’ own personal views and interpretations.

At the 2023 San Antonio Breast Cancer Symposium, Dr. Rena Callahan reviews the difference between Oncotype DX and the Breast Cancer Index test in helping determine treatment plans for women with early-stage, HR breast cancer. Watch here: https://bit.ly/44BkJA5 For intended use and limitations, visit breastcancerindex.com. Speakers listed are consultants for Biotheranostics, Inc. Statements reflect the speakers’ own personal views and interpretations.

Learn from Rena Callahan, MD* and Katherine Cohen, NP* on how they partner to provide personalized care for their patients by using the Breast Cancer Index test® for extended endocrine therapy treatment decisions. Watch here: https://bit.ly/3zv9aPx

At the 2023 JADPRO Live, Marla Sustin, NP reviews a Breast Cancer Index patient case study and reveals how one patient changed her decision regarding extended endocrine therapy following BCI results. Watch here: https://bit.ly/3Wwxqdp For intended use and limitations, visit breastcancerindex.com. Speakers listed are consultants for Biotheranostics, Inc. Statements reflect the speakers’ own personal views and interpretations.

At the 2023 San Antonio Breast Cancer Symposium, Dr. Rena Callahan highlights the impact of the Breast Cancer Index test on patient compliance in regard to extended endocrine therapy. Watch here: https://bit.ly/4br2ZcX For intended use and limitations, visit breastcancerindex.com. Speakers listed are consultants for Biotheranostics, Inc. Statements reflect the speakers’ own personal views and interpretations.

Tune in to hear Rena Callahan, MD* and Katherine Cohen, NP* from UCLA discuss how the Breast Cancer Index® test influences extended endocrine therapy treatment recommendations, sharing the latest data and real-world cases for HR early-stage breast cancer management. Watch here: https://bit.ly/3zv9aPx

At the 2023 JADPRO Live, Linda Moors, PA-C and Mayra Lima, APRN, MSN review the use of the Breast Cancer Index test (BCI) for node-positive patients and highlight BCI’s guideline inclusion. Watch here: https://bit.ly/44EqqNU For intended use and limitations, visit breastcancerindex.com. Speakers listed are consultants for Biotheranostics, Inc. Statements reflect the speakers’ own personal views and interpretations.

How do you manage patients with a high risk of late distant recurrence who are not likely to benefit from extended endocrine therapy? Dr. VK Gadi outlines strategies for managing this type of case at the 2023 San Antonio Breast Cancer Symposium Watch here: https://bit.ly/3yjN0Pr For intended use and limitations, visit breastcancerindex.com. Speakers listed are consultants for Biotheranostics, Inc. Statements reflect the speakers’ own personal views and interpretations.